Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of icaritin in preparation of drugs for treating GP80 related diseases

A kind of technology of Acradine and usage, which is applied in the field of medicine to achieve the effect of good pharmaceutical effect

Inactive Publication Date: 2016-11-23
BEIJING SHENOGEN PHARMA GRP
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In the prior art, there is no further research on other targets other than ER-α36 by Alcoradine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of icaritin in preparation of drugs for treating GP80 related diseases
  • Use of icaritin in preparation of drugs for treating GP80 related diseases
  • Use of icaritin in preparation of drugs for treating GP80 related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Preparation of Alcoradine

[0033] Acradine, also known as icariin, is extracted and separated from the traditional Chinese medicine Epimedium.

[0034] The preparation method of Epimedium is disclosed in the patent whose publication number is CN 101302548. In the method, icariin is used as a raw material, hydrolyzed by β-glucosidase, the precipitate obtained by centrifuging the hydrolyzed product is dissolved in acetone, and the supernatant is obtained by centrifuging and filtering. Then the supernatant liquid obtained by centrifugation is recrystallized with water to obtain the pure Epimedium. The icariin in the present invention was purchased from Shaanxi Jiahe Plant Chemical Co., Ltd., with a purity of 90%.

Embodiment 2

[0036] Detect the inhibitory effects of alcoladine on hepatocarcinoma PLC / PRF / 5 cells.

[0037] Experimental steps: cell culture: first, the PLC / PRF / 5 liver cancer cells are cultured to a cell density of 80% in an amino acid and glucose medium (i.e., DMEM medium) containing a volume concentration of 10% fetal bovine serum; The cells were divided into a phenol red-free medium containing activated carbon-treated fetal bovine serum at a volume concentration of 2.5% by volume, and cultured for 24 hours.

[0038] Add dimethyl sulfoxide (DMSO) and alcradine: add DMSO control (i.e. DMSO solution not containing alcradine) and 5 μM alcradine DMSO solution respectively in the culture system, and make each reaction system The final volume concentration of DMSO in the medium was 0.1%.

[0039] The cells were harvested at 12, 24 and 48 hours respectively, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody and GP80 (IL-6R) antibody were added to the cells for western blot detect...

Embodiment 3

[0042] To detect the inhibitory effects of alcoladine on liver cancer cells HUH-7.

[0043] Experimental steps: cell culture: first, HUH-7 cells were cultured in an amino acid and glucose medium (i.e. DMEM medium) containing 10% volume concentration of fetal bovine serum to a cell density of about 80%; then the cultured cells were divided into Cultured for 24 hours in a phenol red-free medium containing activated carbon-treated fetal bovine serum at a volume concentration of 2.5%.

[0044] Add dimethyl sulfoxide (DMSO) and alcradine: add DMSO control (that is, the DMSO solution that does not contain alcradine) and the alcladine DMSO solution of 5 μ M concentration respectively in the culture system, and make each The final volume concentration of DMSO in the reaction system was 0.1%.

[0045] The cells were harvested at 12, 24 and 48 hours respectively, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and GP80 antibodies were added to the cells for western blot detection....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the use of alcladinine in the preparation of medicines for diseases related to GP80, especially for liver cancer related to GP80, alcladine has shown good pharmaceutical effects. The present invention provides a further research direction for the targeting of alcradine in the treatment of cancer.

Description

technical field [0001] The invention relates to the use of alcradine in the preparation of medicines for treating GP80-related diseases, and belongs to the field of medicine. Background technique [0002] GP80, also known as IL-6R or IL-6Rα, interleukin-6 receptor, has a molecular weight of 80 kDa and is a transmembrane glycoprotein containing 449 amino acids. GP80 acts as a receptor for cytokine IL-6, and cytokine IL-6 exerts its biological activity through its receptor GP80 and molecule GP130. Unlike GP130, which is expressed on all cells, GP80 is only expressed on a few cells in the human body, including liver cells and leukemia cells. [0003] Studies have confirmed that the abnormal activation of IL-6 / GP130 (IL-6 / GP130) signaling pathway plays a key role in the development of various tumors. An article titled "IL6-GP130-STAT3 pathway in liver cells forms T-cell-mediated liver injury hepatoprotection" was published in "The Journal of Clinical Investigation" (The IL-6- ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P35/00A61P1/16
Inventor 孟坤郭玉明朱海王媛媛李抒
Owner BEIJING SHENOGEN PHARMA GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com